Tarun Keswani

Dr. Tarun Keswani


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KLKARTHIK LOGANATHAN
KARTHIK LOGANATHAN
Gaurav KumarGaurav Kumar
Gaurav Kumar
TKTarun Keswani
Tarun Keswani
ABArindam Bhattacharyya
Arindam Bhattacharyya
SCS Sarath Chandar
S Sarath Chandar
KRKokati Venkata Bhaskara Rao
Kokati Venkata Bhaskara Rao
The study was planned to screen the marine actinobacterial extract for the protease inhibitor activity and its anti- Pf activity under in vitro and in vivo conditions. Out of 100 isolates, only 3 isolates exhibited moderate to high protease inhibitor activities on trypsin, chymotrypsin and proteinase K. Based on protease inhibitor activity 3 isolates were chosen for further studies. The potential isolate was characterized by polyphasic approach and identified as Streptomyces sp LK3 (JF710608). The lead compound was identified as peptide from Streptomyces sp LK3. The double-reciprocal plot displayed inhibition mode is non-competitive and it confirms the irreversible nature of protease inhibitor. The peptide from Streptomyces sp LK3 extract showed significant anti plasmodial activity (IC50: 25.78 µg/ml). In in vivo model, the highest level of parasitemia suppression (≈45%) was observed in 600 mg/kg of the peptide. These analyses revealed no significant changes were observed in the spleen and liver tissue during 8 dpi. The results confirmed up-regulation of TGF-β and down regulation of TNF-α in tissue and serum level in PbA infected peptide treated mice compared to PbA infection. The results obtained infer that the peptide possesses anti- Pf activity activity. It suggests that the extracts have novel metabolites and could be considered as a potential source for drug development.

1 October 2013 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
KLKARTHIK LOGANATHAN
KARTHIK LOGANATHAN
Gaurav KumarGaurav Kumar
Gaurav Kumar
TKTarun Keswani
Tarun Keswani
ABArindam Bhattacharyya
Arindam Bhattacharyya
BRB. Palakshi Reddy
B. Palakshi Reddy
KRKokati Venkata Bhaskara Rao
Kokati Venkata Bhaskara Rao

17 January 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NLNicole A. LaHood
Nicole A. LaHood
JMJungki Min
Jungki Min
TKTarun Keswani
Tarun Keswani
CRCrystal M. Richardson
Crystal M. Richardson
KAKwasi Amoako
Kwasi Amoako
SPSarita U. Patil
Sarita U. Patil
In IgE-mediated food allergies, exposure to the allergen activates systemic allergic responses. Oral immunotherapy (OIT) treats food allergies through incremental increases in oral allergen exposure. However, OIT only induces sustained clinical tolerance and decreased basophil sensitivity in a subset of individuals despite increases in circulating allergen-specific IgG in all treated individuals. Therefore, we examined the allergen-specific antibodies from 2 OIT cohorts of patients with sustained and transient responses. Here, we compared antibodies from individuals with sustained or transient responses and discovered specific tolerance-associated conformational epitopes of the immunodominant allergen Ara h 2 recognized by neutralizing antibodies. First, we identified what we believe to be previously unknown conformational, intrahelical epitopes using x-ray crystallography with recombinant antibodies. We then identified epitopes only recognized in sustained tolerance. Finally, antibodies recognizing tolerance-associated epitopes effectively neutralized allergen to suppress IgE-mediated effector cell activation. Our results demonstrate the molecular basis of antibody-mediated protection in IgE-mediated food allergy, by defining how these antibodies disrupt IgE-allergen interactions to prevent allergic reactions. Our approach to studying the structural and functional basis for neutralizing antibodies demonstrates the clinical relevance of specific antibody clones in antibody-mediated tolerance. We anticipate that our findings will form the foundation for treatments of peanut allergy using neutralizing antibodies and hypoallergens.

1 March 2012 in Toxicology
Verified
Journal Article
Closed access
SMSoham Mitra
Soham Mitra
TKTarun Keswani
Tarun Keswani
MDManali Dey
Manali Dey
SBShaswati Bhattacharya
Shaswati Bhattacharya
SSSamrat Sarkar
Samrat Sarkar
ABArindam Bhattacharyya
Arindam Bhattacharyya


1 April 2013 in Toxicology
Verified
Journal Article
Closed access
SMSoham Mitra
Soham Mitra
TKTarun Keswani
Tarun Keswani
NGNabanita Ghosh
Nabanita Ghosh
SGSuranjana Goswami
Suranjana Goswami
ADAnuradha Datta
Anuradha Datta
ABArindam Bhattacharyya
Arindam Bhattacharyya